Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aref Al-Kali

Showing results (31-40 of 148) with videos related to

Pageof 15
Sort By:
American Journal of Hematology|January 10, 2023
A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expressionAref Al-Kali, Raoul Tibes, Pamela Atherton, et al.
Haematologica|November 8, 2011
Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patientsAref Al-Kali, Sergej Konoplev, Erpei Lin, et al.
Oncotarget|May 5, 2016
Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axisXiaojuan Yang, Jiuxia Pang, Na Shen, et al.
Clinical Colorectal Cancer|September 17, 2008
Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 casesMichael J Overman, David Fogelman, Aref Al-Kali, et al.
Haematologica|March 20, 2025
Predictors of response to pacritinib therapy and survival among 60 Mayo Clinic patients with myelofibrosis treated outside of clinical trialsMaymona Abdelmagid, Jeanne M Palmer, Aref Al-Kali, et al.
International Journal of Cancer|October 13, 2015
Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparisonBelal Firwana, Mohamad Bassam Sonbol, Maria Diab, et al.
British Journal of Haematology|November 3, 2021
Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive casesAyalew Tefferi, Jaya Kittur, Faiqa Farrukh, et al.
American Journal of Hematology|September 29, 2023
Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative casesAyalew Tefferi, Maymona Abdelmagid, Aref Al-Kali, et al.
Cancer|April 12, 2023
Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasmsRaoul Tibes, Heidi E Kosiorek, Amylou C Dueck, et al.
American Journal of Hematology|October 13, 2017
Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMMLMrinal M Patnaik, Rangit Vallapureddy, Fevzi F Yalniz, et al.
Pageof 15

Showing results (31-40 of 148) with videos related to

Sort By:
Pageof 15
American Journal of Hematology|January 10, 2023
A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expressionAref Al-Kali, Raoul Tibes, Pamela Atherton, et al.
Haematologica|November 8, 2011
Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patientsAref Al-Kali, Sergej Konoplev, Erpei Lin, et al.
Oncotarget|May 5, 2016
Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axisXiaojuan Yang, Jiuxia Pang, Na Shen, et al.
Clinical Colorectal Cancer|September 17, 2008
Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 casesMichael J Overman, David Fogelman, Aref Al-Kali, et al.
Haematologica|March 20, 2025
Predictors of response to pacritinib therapy and survival among 60 Mayo Clinic patients with myelofibrosis treated outside of clinical trialsMaymona Abdelmagid, Jeanne M Palmer, Aref Al-Kali, et al.
International Journal of Cancer|October 13, 2015
Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparisonBelal Firwana, Mohamad Bassam Sonbol, Maria Diab, et al.
British Journal of Haematology|November 3, 2021
Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive casesAyalew Tefferi, Jaya Kittur, Faiqa Farrukh, et al.
American Journal of Hematology|September 29, 2023
Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative casesAyalew Tefferi, Maymona Abdelmagid, Aref Al-Kali, et al.
Cancer|April 12, 2023
Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasmsRaoul Tibes, Heidi E Kosiorek, Amylou C Dueck, et al.
American Journal of Hematology|October 13, 2017
Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMMLMrinal M Patnaik, Rangit Vallapureddy, Fevzi F Yalniz, et al.
Pageof 15